Mesoblast's (ASX:MSB) Ryoncil is now available for purchase in the US, according to a Thursday filing with the Australian bourse.
Ryoncil is a US Food and Drug Administration-approved therapy for treating pediatric patients aged two months and above, including adolescents and teenagers, with steroid-refractory acute graft versus host disease or SR-aGvHD, per the filing.
Mesoblast's shares were up over 1% in recent Thursday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。